The Phase II trial of arsenic trioxide combined with ascorbic acid for the treatment of non-APL AML addresses a significant unmet need in a challenging patient population that has limited treatment options. Given the historical use of arsenic in medicine and emerging data supporting its efficacy in blood cancers, this combination therapy could provide a novel treatment avenue. However, the trial was terminated due to competing studies, which may impact its commercial viability. Stakeholders should consider the competitive landscape and the necessity for further differentiation in treatment protocols to capture market share in the AML space.